Meg is a communications consultant on the speed-dials of countless healthcare C-Suite executives. Over nearly 15 years, she has helped Fortune 500 companies successfully navigate some of the most challenging issues facing their industries – tackling issues involving the affordability of medicines, recalls, compassionate use campaigns, lawsuits, activist attacks and more. Meg’s areas of expertise include addressing forms of modern activism, navigating new populism, and helping healthcare companies avoid drug pricing crises. Her passionate advocacy for her clients and innovative approach have secured recognitions of as a “Disruptor” and a “Rising Star” by PM360 and the Healthcare Business Women’s Association.
B2 is part of INC Research/inVentiv Health, an industry-changing new company, purpose-built to help the industry achieve a singular goal: Biopharmaceutical Acceleration. The coming together of two dedicated businesses allows us to address new market realities through clinical and commercial sharing expertise, data and insights to meet the needs of global biopharmaceutical companies of all sizes to speed the delivery of therapies to patients worldwide.